Gene and isoform expression signatures associated with tumor stage in kidney renal clear cell carcinoma

BMC Systems Biology

Volumn 7, Issue SUPPL 5, 2013, Pages

  Liu, Qi ^a   Zhao, Shilin ^a   Su, Pei Fang ^b   Yu, Shyr ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN;

ARTICLE; CANCER STAGING; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR GENE;

CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION PROFILING; GENES, NEOPLASM; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTEIN ISOFORMS;

EID: 84889669175     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-7-S5-S7     Document Type: Article

References (60)

1. Yokota J. Tumor progression and metastasis. Carcinogenesis 2000, 21(3):497-503. 10.1093/carcin/21.3.497, 10688870.
2. Cui J, Li F, Wang G, Fang X, Puett JD, Xu Y. Gene-expression signatures can distinguish gastric cancer grades and stages. PLoS One 2011, 6(3):e17819. 10.1371/journal.pone.0017819, 3060867, 21445269.
3. Delgado-Cruzata L, Hruby GW, Gonzalez K, McKiernan J, Benson MC, Santella RM, Shen J. DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer. DNA Cell Biol 2012, 31(2):187-192. 10.1089/dna.2011.1311, 3272239, 21830905.
4. Dip N, Reis ST, Timoszczuk LS, Viana NI, Piantino CB, Morais DR, Moura CM, Abe DK, Silva IA, Srougi M, et al. Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile. J Urol 2012, 188(5):1951-1956. 10.1016/j.juro.2012.07.004, 22999546.
5. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61(5):759-767. 10.1016/0092-8674(90)90186-I, 2188735.
6. Fransson S, Abel F, Kogner P, Martinsson T, Ejeskar K. Stage-dependent expression of PI3K/Aktpathway genes in neuroblastoma. Int J Oncol 2013, 42(2):609-616.
7. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87(2):159-170. 10.1016/S0092-8674(00)81333-1, 8861899.
8. Oue N, Mitani Y, Motoshita J, Matsumura S, Yoshida K, Kuniyasu H, Nakayama H, Yasui W. Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer 2006, 106(6):1250-1259. 10.1002/cncr.21754, 16475210.
9. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010, 138(3):958-968. 10.1053/j.gastro.2009.11.005, 3388775, 19914252.
10. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 1988, 319(9):525-532. 10.1056/NEJM198809013190901, 2841597.
11. Watts GS, Futscher BW, Holtan N, Degeest K, Domann FE, Rose SL. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics 2008, 1:47. 10.1186/1755-8794-1-47, 2566571, 18826610.
12. Mannan A, Hahn-Stromberg V. K-ras mutations are correlated to lymph node metastasis and tumor stage, but not to the growth pattern of colon carcinoma. APMIS 2012, 120(6):459-468. 10.1111/j.1600-0463.2011.02852.x, 22583358.
13. Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith DR, Goh HS, Joseph D, Iacopetta B. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 2000, 36(16):2053-2060. 10.1016/S0959-8049(00)00285-9, 11044641.
14. Zhang Q, Ying J, Li J, Fan Y, Poon FF, Ng KM, Tao Q, Jin J. Aberrant promoter methylation of DLEC1, a critical 3p22 tumor suppressor for renal cell carcinoma, is associated with more advanced tumor stage. J Urol 2010, 184(2):731-737. 10.1016/j.juro.2010.03.108, 20639048.
15. Zhu X, Qin X, Fei M, Hou W, Greshock J, Bachman KE, Kang J, Qin CY. Loss and reduced expression of PTEN correlate with advanced-stage gastric carcinoma. Exp Ther Med 2013, 5(1):57-64. 3524019, 23251242.
16. Apostolou P, Toloudi M, Chatziioannou M, Ioannou E, Papasotiriou I. Cancer stem cells stemness transcription factors expression correlates with breast cancer disease stage. Curr Stem Cell Res Ther 2012, 7(6):415-419. 10.2174/157488812804484639, 23061814.
17. Okamura K, Koike H, Sekine Y, Matsui H, Suzuki K. Survivin and its spliced isoform gene expression is associated with proliferation of renal cancer cells and clinical stage of renal cancer. Cancer Epidemiol 2009, 33(2):137-141. 10.1016/j.canep.2009.06.005, 19679061.
18. Tomlinson DC, Knowles MA. Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer. Am J Pathol 2010, 177(5):2379-2386. 10.2353/ajpath.2010.100354, 2966796, 20889570.
19. Marabese M, Marchini S, Marrazzo E, Mariani P, Cattaneo D, Fossati R, Compagnoni A, Signorelli M, Moll UM, Codegoni AM, et al. Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. Eur J Cancer 2008, 44(1):131-141. 10.1016/j.ejca.2007.10.011, 18039564.
20. Terpe HJ, Storkel S, Zimmer U, Anquez V, Fischer C, Pantel K, Gunthert U. Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. Am J Pathol 1996, 148(2):453-463. 1861693, 8579108.
21. Zhou YJ, Xie YT, Gu J, Yan L, Guan GX, Liu X. Overexpression of cyclin E isoforms correlates with poor prognosis in rectal cancer. Eur J Surg Oncol 2011, 37(12):1078-1084. 10.1016/j.ejso.2011.08.139, 21944050.
22. Karni-Schmidt O, Castillo-Martin M, Shen TH, Gladoun N, Domingo-Domenech J, Sanchez-Carbayo M, Li Y, Lowe S, Prives C, Cordon-Cardo C. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol 2011, 178(3):1350-1360. 10.1016/j.ajpath.2010.11.061, 3069841, 21356385.
23. Ghigna C, Valacca C, Biamonti G. Alternative splicing and tumor progression. Curr Genomics 2008, 9(8):556-570. 10.2174/138920208786847971, 2694562, 19516963.
24. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009, 10(1):57-63. 10.1038/nrg2484, 2949280, 19015660.
25. Griffith M, Griffith OL, Mwenifumbo J, Goya R, Morrissy AS, Morin RD, Corbett R, Tang MJ, Hou YC, Pugh TJ, et al. Alternative expression analysis by RNA sequencing. Nat Methods 2010, 7(10):843-847. 10.1038/nmeth.1503, 20835245.
26. Nicolae M, Mangul S, Zelikovsky A. Estimation of alternative splicing isoform frequencies from RNA-Seq data. Algorithms Mol Biol 2011, 6(1):9. 10.1186/1748-7188-6-9, 3107792, 21504602.
27. Huang Y, Hu Y, Jones CD, Macleod JN, Chiang DY, Liu Y, Prins JF, Liu J. A Robust Method for Transcript Quantification with RNA-Seq Data. J Comput Biol 2013, 20(3):167-187. 10.1089/cmb.2012.0230, 23461570.
28. Katz Y, Wang ET, Airoldi EM, Burge CB. Analysis and design of RNA sequencing experiments for identifying isoform regulation. Nat Methods 2010, 7(12):1009-1015. 10.1038/nmeth.1528, 3037023, 21057496.
29. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010, 28(5):511-515. 10.1038/nbt.1621, 3146043, 20436464.
30. Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L. Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat Biotechnol 2013, 31(1):46-53.
31. Mezlini AM, Smith EJ, Fiume M, Buske O, Savich GL, Shah S, Aparicio S, Chiang DY, Goldenberg A, Brudno M. iReckon: Simultaneous isoform discovery and abundance estimation from RNA-seq data. Genome Res 2013, 23(3):519-529. 10.1101/gr.142232.112, 3589540, 23204306.
32. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 2011, 12:323. 10.1186/1471-2105-12-323, 3163565, 21816040.
33. Li J, Jiang H, Wong WH. Modeling non-uniformity in short-read rates in RNA-Seq data. Genome Biol 2010, 11(5):R50. 10.1186/gb-2010-11-5-r50, 2898062, 20459815.
34. Garber M, Grabherr MG, Guttman M, Trapnell C. Computational methods for transcriptome annotation and quantification using RNA-seq. Nat Methods 2011, 8(6):469-477. 10.1038/nmeth.1613, 21623353.
35. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Statistical applications in genetics and molecular biology 2004, 3:Article3.
36. Monti S, Tamayo P, Mesirov J, Golub T. Consensus clustering: A resampling-based method for class discovery and visualization of gene expression microarray data. Mach Learn 2003, 52(1-2):91-118.
37. Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 2010, 26(12):1572-1573. 10.1093/bioinformatics/btq170, 2881355, 20427518.
38. Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 2005, 33(Web Server):W741-748. 10.1093/nar/gki475, 1160236, 15980575.
39. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004, 4(1):11-22.
40. Tsujimoto H, Ono S, Ichikura T, Matsumoto Y, Yamamoto J, Hase K. Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes?. Gastric Cancer 2010, 13(4):212-221. 10.1007/s10120-010-0568-x, 21128056.
41. Chung YC, Chang YF. Significance of inflammatory cytokines in the progression of colorectal cancer. Hepatogastroenterology 2003, 50(54):1910-1913.
42. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989, 250(2):607-610. 10.1016/0014-5793(89)80805-1, 2787758.
43. Pazienza V, Vinciguerra M, Mazzoccoli G. PPARs Signaling and Cancer in the Gastrointestinal System. PPAR Res 2012, 2012:560846. 3458283, 23028383.
44. Capiod T, Shuba Y, Skryma R, Prevarskaya N. Calcium signalling and cancer cell growth. Subcell Biochem 2007, 45:405-427. 10.1007/978-1-4020-6191-2_15, 18193646.
45. Windhorst S, Fliegert R, Blechner C, Mollmann K, Hosseini Z, Gunther T, Eiben M, Chang L, Lin HY, Fanick W, et al. Inositol 1,4,5-trisphosphate 3-kinase-A is a new cell motility-promoting protein that increases the metastatic potential of tumor cells by two functional activities. J Biol Chem 2010, 285(8):5541-5554. 10.1074/jbc.M109.047050, 2820782, 20022963.
46. Gerhardt J, Montani M, Wild P, Beer M, Huber F, Hermanns T, Muntener M, Kristiansen G. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. Am J Pathol 2012, 180(2):848-861. 10.1016/j.ajpath.2011.10.021, 22138582.
47. Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, Sankila A, Turunen JP, Lundin M, Konsti J, et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J 2011, 30(19):3962-3976. 10.1038/emboj.2011.328, 3209787, 21915096.
48. Chang YW, Marlin JW, Chance TW, Jakobi R. RhoA mediates cyclooxygenase-2 signaling to disrupt the formation of adherens junctions and increase cell motility. Cancer Res 2006, 66(24):11700-11708. 10.1158/0008-5472.CAN-06-1818, 17178865.
49. Boissan M, De Wever O, Lizarraga F, Wendum D, Poincloux R, Chignard N, Desbois-Mouthon C, Dufour S, Nawrocki-Raby B, Birembaut P, et al. Implication of metastasis suppressor NM23-H1 in maintaining adherens junctions and limiting the invasive potential of human cancer cells. Cancer Res 2010, 70(19):7710-7722. 10.1158/0008-5472.CAN-10-1887, 20841469.
50. Vasioukhin V. Adherens junctions and cancer. Subcell Biochem 2012, 60:379-414. 10.1007/978-94-007-4186-7_16, 22674080.
51. Martin TA, Mason MD, Jiang WG. Tight junctions in cancer metastasis. Front Biosci 2011, 16:898-936.
52. Martin TA, Jiang WG. Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta 2009, 1788(4):872-891. 10.1016/j.bbamem.2008.11.005, 19059202.
53. Glaunsinger BA, Weiss RS, Lee SS, Javier R. Link of the unique oncogenic properties of adenovirus type 9 E4-ORF1 to a select interaction with the candidate tumor suppressor protein ZO-2. EMBO J 2001, 20(20):5578-5586. 10.1093/emboj/20.20.5578, 125668, 11598001.
54. Gonzalez-Mariscal L, Tapia R, Huerta M, Lopez-Bayghen E. The tight junction protein ZO-2 blocks cell cycle progression and inhibits cyclin D1 expression. Ann N Y Acad Sci 2009, 1165:121-125. 10.1111/j.1749-6632.2009.04024.x, 19538296.
55. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002, 29(6 Suppl 16):15-18.
56. Pralhad T, Madhusudan S, Rajendrakumar K. Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. J Pharm Pharmacol 2003, 55(8):1045-1053. 10.1211/0022357021819, 12956893.
57. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000, 407(6801):249-257. 10.1038/35025220, 11001068.
58. Mei Y, Hahn AA, Hu S, Yang X. The USP19 deubiquitinase regulates the stability of c-IAP1 and c-IAP2. J Biol Chem 2011, 286(41):35380-35387. 10.1074/jbc.M111.282020, 3195621, 21849505.
59. Pickrell JK, Pai AA, Gilad Y, Pritchard JK. Noisy splicing drives mRNA isoform diversity in human cells. PLoS Genet 2010, 6(12):e1001236. 10.1371/journal.pgen.1001236, 3000347, 21151575.
60. Chen L, Tovar-Corona JM, Urrutia AO. Increased levels of noisy splicing in cancers, but not for oncogene-derived transcripts. Hum Mol Genet 2011, 20(22):4422-4429. 10.1093/hmg/ddr370, 3196890, 21862452.